Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2.

Neurotherapeutics

Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA; Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University in St Louis, St Louis, MO, USA. Electronic address:

Published: January 2025

Autosomal dominant Alzheimer's disease (ADAD) is driven by rare variants in APP, PSEN1, and PSEN2. Although more than 200 pathogenic variants in these genes are known to cause ADAD, other variants are benign, may act as risk factors, or may even reduce Alzheimer's disease risk (e.g. protective). Classifying novel variants in APP, PSEN1, or PSEN2 as pathogenic, risk, benign, or protective is a critical step in evaluating disease risk profiles which further impacts eligibility for clinical trials focused on the ADAD population. Here, we classify 53 novel variants in APP, PSEN1, and PSEN2 based on bioinformatic data and cell-based assays. We identified 6 benign variants, 2 risk variants, and 32 likely pathogenic variants. Thirteen variants were associated with reduced Aβ levels in cell-based assays, consistent with a potential protective effect. Together, this study highlights the complexities associated with classification of rare variants in ADAD genes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurot.2025.e00527DOI Listing

Publication Analysis

Top Keywords

app psen1
16
psen1 psen2
16
variants app
12
variants
11
alzheimer's disease
8
rare variants
8
pathogenic variants
8
disease risk
8
novel variants
8
cell-based assays
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!